These findings suggest that IRF4 has the potential to alter the developmental fate (e.g., lineage switching) of hematopoietic progenitors, and its downregulation may endow immature myeloid malignancies with MDSC-like properties. The gene discussed is IRF4; the disease is myeloid neoplasm.